Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Prospective Cohort Study
Jeffrey A. Sparks,Xintong He,Jie Huang,Elaine A. Fletcher,Alessandra Zaccardelli,H. Maura Friedlander,Ritu R. Gill,Hiroto Hatabu,Mizuki Nishino,David J. Murphy,Christine K. Iannaccone,Taysir G. Mahmoud,Michelle L. Frits,Bing Lu,Ivan O. Rosas,Paul F. Dellaripa,Michael E. Weinblatt,Elizabeth W. Karlson,Nancy A. Shadick,Tracy J. Doyle
DOI: https://doi.org/10.1002/art.40904
2019-08-04
Abstract:To evaluate rheumatoid arthritis (RA) disease activity and risk for RA‐associated interstitial lung disease (RA‐ILD).We investigated disease activity and RA‐ILD risk using the Brigham RA Sequential Study (BRASS, 2003‐2016). All subjects had RA according to accepted criteria. Disease activity scores using 28 joints (DAS28) and covariate data were measured prospectively at annual study visits. RA‐ILD was determined by research review of images from clinically‐indicated chest computed tomography scans. We analyzed subjects without RA‐ILD at baseline. Cox regression estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for RA‐ILD by time‐updated DAS28 categories, adjusting for known RA‐ILD risk factors (age, sex, smoking, RA duration, and serologic status). We performed alternative analyses not censoring after missing DAS28 and adjusting for methotrexate/glucocorticoids/bone erosions/rheumatoid nodules.Among 1,419 participants, mean age was 55.8 years (SD 14.2) and 68.6% were seropositive. We identified 85 incident RA‐ILD cases during mean 8.9 years (SD 4.2) of follow‐up/subject. Moderate/high disease activity had multivariable HR of 2.22 (95%CI 1.28‐3.82) for RA‐ILD compared to remission/low. Risk for RA‐ILD increased across disease activity categories; multivariable HRs(95%CIs) were: 1.00(reference) for remission, 1.41(0.61‐3.28) for low, 2.08(1.06‐4.05) for moderate, and 3.48(1.64‐7.38) for high (<i>p</i> trend=0.001). For every unit increase in DAS28, RA‐ILD risk increased by 35% (95%CI 14‐60%). Results were similar in analyses including follow‐up after missing DAS28 and adjusting for methotrexate, glucocorticoids, bone erosions, or rheumatoid nodules. Active RA was associated with increased risk for developing RA‐ILD. These results suggest that decreasing systemic inflammation may alter the natural history of RA‐ILD development.This article is protected by copyright. All rights reserved.
rheumatology